New 'Armored' cell therapy tested in fight against deadly brain cancer
NCT ID NCT07193628
Summary
This is a first-in-human, early-stage trial testing the safety and initial effectiveness of a new type of CAR-T cell therapy called EPC-003 for adults with recurrent or treatment-resistant glioblastoma, a serious brain cancer. The therapy involves collecting and genetically modifying a patient's own immune cells to target two specific proteins found on the cancer cells, then injecting them back into the brain fluid. The study will first test increasing doses in a small group of up to 14 patients to find a safe amount before expanding treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the Second Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITINGHangzhou, Zhejiang, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.